Bioequivalence of Rotigotine Transdermal Patch Formulations in Healthy Chinese Subjects

Phase 1, randomised, open-label trial of rotigotine in Parkinson's disease (PD) and restless legs syndrome (RLS) (2 arms), sponsored by UCB. Primary endpoints: Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration at 48 hours, Area under the plasma concentration-time curve from zero up to Infinity at 48 hours and 1 more. Started Feb 2014; status: completed.